Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Receivables (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Change in Receivables data on record, last reported at $31.1 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 120.25% year-over-year to $31.1 million; the TTM value through Dec 2025 reached $73.2 million, up 54.81%, while the annual FY2025 figure was $73.2 million, 54.81% up from the prior year.
  • Change in Receivables reached $31.1 million in Q4 2025 per ARQT's latest filing, up from $8.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $31.1 million in Q4 2025 and bottomed at $2.2 million in Q3 2023.
  • Average Change in Receivables over 4 years is $10.4 million, with a median of $7.4 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: soared 651.54% in 2024, then tumbled 49.25% in 2025.
  • A 4-year view of Change in Receivables shows it stood at $6.0 million in 2022, then increased by 6.02% to $6.4 million in 2023, then soared by 121.06% to $14.1 million in 2024, then soared by 120.25% to $31.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $31.1 million in Q4 2025, $8.4 million in Q3 2025, and $21.3 million in Q2 2025.